Epigenetics Diagnostic Market Research Report 2033

Epigenetics Diagnostic Market Research Report 2033

Segments - by Product Type (Kits, Reagents, Instruments, Software), by Technology (DNA Methylation, Histone Modification, Non-coding RNA Analysis, Chromatin Immunoprecipitation, Others), by Application (Oncology, Non-Oncology, Metabolic Diseases, Infectious Diseases, Others), by End-User (Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Others)

https://growthmarketreports.com/raksha
Author : Raksha Sharma
https://growthmarketreports.com/Vaibhav
Fact-checked by : V. Chandola
https://growthmarketreports.com/Shruti
Editor : Shruti Bhat

Upcoming | Report ID :HC-854 | 4.3 Rating | 22 Reviews | 282 Pages | Format : Docx PDF

Report Description


Epigenetics Diagnostic Market Outlook

According to our latest research, the global epigenetics diagnostic market size reached USD 2.82 billion in 2024, driven by robust advancements in molecular diagnostics and growing demand for precision medicine. The market is projected to expand at a CAGR of 13.6% from 2025 to 2033, culminating in a forecasted value of USD 8.95 billion by 2033. This remarkable growth is propelled by increasing adoption of epigenetics-based diagnostic tools in oncology and other disease areas, alongside technological innovations and heightened awareness among clinicians and patients. As per our latest research, the market’s upward trajectory is further supported by expanding applications across diverse healthcare segments and rising investments in research and development.

One of the primary growth factors for the epigenetics diagnostic market is the increasing prevalence of cancer and other chronic diseases worldwide. The growing understanding that epigenetic modifications, such as DNA methylation and histone modifications, play a pivotal role in the onset and progression of diseases has led to a surge in demand for precise and early diagnostic tools. As a result, healthcare providers and researchers are increasingly adopting epigenetics-based assays to improve early detection, prognosis, and therapeutic decision-making. The integration of these diagnostics into routine clinical workflows not only enhances patient outcomes but also drives the overall market growth by expanding the addressable patient pool and enabling more targeted treatments.

Another significant driver is the continuous technological advancements in epigenetics research and diagnostics. The development of highly sensitive and specific kits, reagents, and instruments has revolutionized the field, enabling more accurate detection of subtle epigenetic changes at the molecular level. Next-generation sequencing (NGS), chromatin immunoprecipitation (ChIP), and advanced PCR-based methods have all contributed to the increased reliability and scalability of epigenetic testing. Additionally, the integration of artificial intelligence and bioinformatics tools for data analysis has streamlined the interpretation of complex epigenetic data, making these diagnostics more accessible to clinicians and researchers. These technological improvements are instrumental in lowering costs, reducing turnaround times, and enhancing the clinical utility of epigenetics diagnostics.

The expanding scope of applications beyond oncology is also fueling market growth. While cancer diagnostics remain the dominant application, there is increasing recognition of the role of epigenetic mechanisms in a wide range of non-oncological conditions, including metabolic, infectious, and neurodegenerative diseases. This has opened new avenues for the use of epigenetic biomarkers in early disease detection, risk stratification, and personalized medicine. Pharmaceutical and biotechnology companies are leveraging these insights to develop novel therapeutics and companion diagnostics, further boosting demand for epigenetics-based solutions. This diversification of applications not only broadens the market’s reach but also enhances its resilience to fluctuations in any single disease segment.

Regionally, North America continues to dominate the epigenetics diagnostic market, accounting for the largest share in 2024, followed by Europe and the Asia Pacific. The strong presence of leading biotechnology companies, well-established healthcare infrastructure, and significant investments in research and development contribute to the region’s leadership. However, the Asia Pacific region is poised for the fastest growth over the forecast period, driven by increasing healthcare expenditure, rising awareness of precision diagnostics, and expanding access to advanced medical technologies in countries such as China, Japan, and India. These regional dynamics are reshaping the competitive landscape and creating new opportunities for market players across the globe.

Global Epigenetics Diagnostic Industry Outlook

Product Type Analysis

The epigenetics diagnostic market by product type is segmented into kits, reagents, instruments, and software. Kits represent a substantial portion of the market, as they offer comprehensive solutions for the rapid and reliable analysis of epigenetic modifications, particularly in clinical and research settings. The convenience, reproducibility, and ease of use provided by commercial kits have made them highly popular among diagnostic laboratories and academic institutions. These kits are designed for a variety of applications, including DNA methylation analysis, histone modification detection, and chromatin immunoprecipitation, meeting the diverse needs of end-users. The continuous launch of new and improved kits by leading manufacturers further strengthens this segment’s dominance and drives overall market growth.

Reagents form another critical segment, essential for the execution of various epigenetic assays. High-quality reagents such as enzymes, buffers, and antibodies are integral to the accuracy and sensitivity of diagnostic procedures. The growing adoption of advanced reagents tailored for specific technologies, such as next-generation sequencing and PCR-based methods, has significantly improved the performance of epigenetics diagnostics. Suppliers are investing in the development of reagents with higher specificity and stability, catering to the evolving requirements of both research and clinical laboratories. This focus on reagent innovation is crucial in maintaining the reliability and reproducibility of diagnostic results, thereby supporting the market’s expansion.

Instruments play a pivotal role in the epigenetics diagnostic workflow, enabling the automation and high-throughput analysis of complex biological samples. Sophisticated platforms such as sequencers, real-time PCR machines, and chromatin immunoprecipitation systems have become indispensable in modern laboratories. The integration of automation and digitalization in instruments has not only enhanced throughput and efficiency but also minimized human error, resulting in more consistent and accurate diagnostic outcomes. As demand for high-throughput and multiplexed assays continues to rise, instrument manufacturers are focusing on developing scalable, user-friendly, and cost-effective solutions to address the growing needs of the market.

Software solutions are increasingly important in the epigenetics diagnostic market, as they facilitate the management, analysis, and interpretation of vast and complex datasets generated by modern diagnostic platforms. Advanced bioinformatics tools and data analytics platforms enable researchers and clinicians to extract meaningful insights from epigenetic data, supporting more informed clinical decision-making. Software integration is especially critical for multi-omics approaches, where the convergence of genomics, transcriptomics, and epigenomics data requires sophisticated computational resources. The ongoing evolution of software tools, coupled with the adoption of artificial intelligence and machine learning, is expected to further enhance the value proposition of epigenetics diagnostics.

Report Scope

Attributes Details
Report Title Epigenetics Diagnostic Market Research Report 2033
By Product Type Kits, Reagents, Instruments, Software
By Technology DNA Methylation, Histone Modification, Non-coding RNA Analysis, Chromatin Immunoprecipitation, Others
By Application Oncology, Non-Oncology, Metabolic Diseases, Infectious Diseases, Others
By End-User Hospitals & Clinics, Diagnostic Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Others
Regions Covered North America, Europe, APAC, Latin America, MEA
Base Year 2024
Historic Data 2018-2023
Forecast Period 2025-2033
Number of Pages 282
Number of Tables & Figures 319
Customization Available Yes, the report can be customized as per your need.

Technology Analysis

The technology landscape in the epigenetics diagnostic market is shaped by several key modalities, including DNA methylation, histone modification, non-coding RNA analysis, chromatin immunoprecipitation, and others. DNA methylation analysis remains the cornerstone of epigenetics diagnostics, owing to its well-established role in gene regulation and disease pathogenesis. Techniques such as methylation-specific PCR, bisulfite sequencing, and array-based methods are widely used for the detection and quantification of methylation patterns, particularly in cancer diagnostics. The growing clinical utility of DNA methylation biomarkers for early detection, prognosis, and therapy selection continues to drive the adoption of these technologies in both research and clinical settings.

Histone modification analysis is another rapidly growing segment, reflecting the increasing recognition of the role of histone marks in chromatin remodeling and gene expression. Techniques such as chromatin immunoprecipitation followed by sequencing (ChIP-seq) have enabled high-resolution mapping of histone modifications across the genome, providing valuable insights into disease mechanisms and potential therapeutic targets. The development of more sensitive and specific antibodies, along with advancements in sequencing technologies, has significantly improved the reliability and scalability of histone modification analysis. This has led to broader adoption in both basic research and translational applications, further supporting market growth.

Non-coding RNA analysis is emerging as a critical component of the epigenetics diagnostic market, driven by growing evidence of the regulatory functions of microRNAs, long non-coding RNAs, and other RNA species. These molecules play key roles in gene expression regulation and are implicated in a wide range of diseases, including cancer, cardiovascular, and neurological disorders. Advanced sequencing and microarray technologies have enabled the comprehensive profiling of non-coding RNAs, facilitating the identification of novel biomarkers and therapeutic targets. The expanding research in this area is expected to translate into new diagnostic applications and fuel further growth in the market.

Chromatin immunoprecipitation (ChIP) technologies are integral to the study of protein-DNA interactions and epigenetic regulation. ChIP-based assays, particularly when combined with next-generation sequencing, allow for the genome-wide identification of binding sites for transcription factors and other chromatin-associated proteins. This technology has become essential for elucidating the complex regulatory networks underlying gene expression and disease development. The increasing availability of high-quality ChIP-grade reagents and user-friendly protocols has facilitated the broader adoption of this technology, making it a key driver of innovation in the epigenetics diagnostic market.

Application Analysis

Oncology remains the largest application segment within the epigenetics diagnostic market, accounting for a significant share of total revenues. The critical role of epigenetic alterations in tumor initiation, progression, and resistance to therapy has made epigenetic biomarkers invaluable for cancer diagnosis, prognosis, and treatment monitoring. DNA methylation and histone modification assays are routinely used to detect cancer-specific epigenetic changes, enabling earlier and more accurate diagnosis. Furthermore, the integration of epigenetics diagnostics into personalized oncology approaches supports the development of targeted therapies and the identification of patients most likely to benefit from specific treatments. This strong focus on oncology is expected to persist, given the ongoing global burden of cancer and the continuous emergence of new epigenetic biomarkers.

Beyond oncology, the market is witnessing growing adoption of epigenetics diagnostics in non-oncological applications, including metabolic, infectious, and autoimmune diseases. Epigenetic mechanisms are increasingly recognized as key contributors to the pathogenesis of conditions such as diabetes, obesity, and cardiovascular diseases. Diagnostic assays targeting specific epigenetic modifications are being developed to enable early detection, risk assessment, and disease monitoring in these patient populations. The expansion of epigenetics diagnostics into non-oncology applications diversifies the market and provides new growth opportunities for manufacturers and service providers.

Metabolic diseases represent a particularly promising area for the application of epigenetics diagnostics. The interplay between genetic, environmental, and epigenetic factors in the development of metabolic disorders has spurred interest in the identification of epigenetic biomarkers for disease prediction and prevention. Research efforts are focused on elucidating the epigenetic signatures associated with insulin resistance, lipid metabolism, and inflammation, with the goal of developing clinically actionable diagnostic tools. The integration of these assays into routine clinical practice could significantly improve patient outcomes and reduce the burden of metabolic diseases on healthcare systems.

Infectious diseases are another important application area, as epigenetic modifications can influence host-pathogen interactions and the immune response. Diagnostic assays that detect epigenetic changes associated with infection or immune activation have the potential to improve the accuracy and timeliness of infectious disease diagnosis. This is particularly relevant in the context of emerging infectious threats and the need for rapid, sensitive diagnostic solutions. The ongoing research into the epigenetic basis of infectious diseases is expected to yield new diagnostic tools and contribute to the overall growth of the epigenetics diagnostic market.

End-User Analysis

Hospitals and clinics represent a major end-user segment for epigenetics diagnostics, as these institutions are at the forefront of adopting advanced diagnostic technologies to improve patient care. The integration of epigenetics assays into hospital laboratories enables the timely and accurate diagnosis of a wide range of diseases, supporting personalized treatment strategies and better clinical outcomes. Hospitals also play a critical role in the validation and implementation of new diagnostic tools, collaborating with research institutions and industry partners to bring innovative solutions to the bedside. The growing emphasis on precision medicine and the need for early detection are expected to drive continued adoption of epigenetics diagnostics in hospitals and clinics.

Diagnostic laboratories constitute another key end-user group, providing specialized testing services to hospitals, clinics, and other healthcare providers. These laboratories are equipped with advanced instrumentation and staffed by skilled personnel, enabling them to perform complex epigenetic assays with high accuracy and throughput. The increasing demand for outsourced diagnostic services, driven by cost considerations and the need for specialized expertise, is fueling the growth of this segment. Diagnostic laboratories also play a vital role in supporting clinical trials and research studies, further expanding their contribution to the epigenetics diagnostic market.

Academic and research institutes are essential to the advancement of epigenetics diagnostics, as they conduct foundational research to uncover the molecular mechanisms underlying disease and develop novel diagnostic approaches. These institutions are often early adopters of cutting-edge technologies and play a crucial role in validating and disseminating new diagnostic tools. Collaborative efforts between academia, industry, and healthcare providers accelerate the translation of research findings into clinically relevant diagnostics, supporting the overall growth and innovation within the market.

Pharmaceutical and biotechnology companies are increasingly leveraging epigenetics diagnostics in drug development and companion diagnostics. The identification of epigenetic biomarkers enables the stratification of patient populations, optimization of clinical trial design, and monitoring of therapeutic responses. These companies are investing in the development of proprietary diagnostic assays and partnering with diagnostic firms to co-develop and commercialize new solutions. The growing emphasis on personalized medicine and targeted therapies is expected to further increase the demand for epigenetics diagnostics among pharmaceutical and biotechnology companies.

Opportunities & Threats

The epigenetics diagnostic market presents significant opportunities, particularly in the context of personalized medicine and the growing emphasis on early disease detection. The ability to identify disease-specific epigenetic changes enables the development of highly targeted diagnostic assays, supporting more precise risk stratification and treatment selection. This, in turn, enhances patient outcomes and reduces healthcare costs by minimizing unnecessary interventions and optimizing therapeutic efficacy. The ongoing expansion of applications beyond oncology, including metabolic, infectious, and neurodegenerative diseases, further broadens the market’s potential and creates new avenues for innovation and growth. Companies that invest in research and development, strategic partnerships, and the development of user-friendly diagnostic solutions are well-positioned to capitalize on these emerging opportunities.

Another major opportunity lies in the integration of artificial intelligence and machine learning into epigenetics diagnostics. Advanced data analytics platforms can facilitate the interpretation of complex multi-omics datasets, enabling the discovery of novel biomarkers and the development of predictive diagnostic models. The adoption of digital health solutions and cloud-based platforms further streamlines data management and sharing, supporting collaborative research and accelerating the translation of research findings into clinical practice. The increasing availability of high-quality biobanks and large-scale population studies also provides valuable resources for the validation and commercialization of new diagnostic assays. As the regulatory environment continues to evolve, companies that demonstrate robust clinical utility and cost-effectiveness of their solutions are likely to gain a competitive edge in the market.

Despite these opportunities, the epigenetics diagnostic market faces several restraining factors, including high costs associated with advanced diagnostic technologies and the complexity of data interpretation. The need for specialized equipment, reagents, and skilled personnel can pose significant barriers to adoption, particularly in resource-limited settings. Additionally, the regulatory landscape for epigenetics diagnostics is still evolving, with varying requirements across different regions and applications. Ensuring the clinical validity, utility, and reproducibility of new assays remains a challenge, necessitating rigorous validation studies and ongoing post-market surveillance. Addressing these challenges will require coordinated efforts among industry stakeholders, regulatory authorities, and healthcare providers to ensure the safe and effective integration of epigenetics diagnostics into clinical practice.

Regional Outlook

North America held the largest share of the global epigenetics diagnostic market in 2024, accounting for approximately 42% of total revenues, or about USD 1.18 billion. The region’s dominance is underpinned by a strong biotechnology sector, advanced healthcare infrastructure, and substantial investments in research and development. The presence of leading diagnostic companies and academic institutions, along with supportive regulatory frameworks, has facilitated the rapid adoption of epigenetics diagnostics in clinical and research settings. The United States, in particular, is a major contributor to the region’s growth, driven by high disease prevalence, increasing demand for personalized medicine, and ongoing innovation in diagnostic technologies. The North American market is expected to maintain steady growth, with a projected CAGR of 12.8% through 2033.

Europe is the second-largest regional market, representing around 29% of global revenues, or approximately USD 0.82 billion in 2024. The region benefits from a robust network of research institutions, strong government support for genomics and precision medicine initiatives, and a growing focus on early disease detection. Countries such as Germany, the United Kingdom, and France are at the forefront of adopting advanced epigenetics diagnostics, supported by well-established healthcare systems and active participation in international research collaborations. The European market is characterized by increasing public and private investments in healthcare innovation, as well as a favorable regulatory environment that encourages the development and commercialization of novel diagnostic solutions.

The Asia Pacific region is poised for the fastest growth over the forecast period, with a projected CAGR of 15.2%. In 2024, the region accounted for about 21% of the global market, or USD 0.59 billion. Rapidly expanding healthcare infrastructure, rising prevalence of chronic diseases, and increasing awareness of the benefits of precision diagnostics are key drivers of market growth in countries such as China, Japan, and India. Government initiatives to promote genomics research, along with growing investments by international and domestic companies, are further accelerating the adoption of epigenetics diagnostics in the region. The Asia Pacific market is expected to outpace other regions in terms of growth rate, presenting significant opportunities for market players seeking to expand their global footprint.

Epigenetics Diagnostic Market Statistics

Competitor Outlook

The competitive landscape of the epigenetics diagnostic market is characterized by the presence of both established multinational corporations and innovative emerging players. The market is highly dynamic, with companies competing on the basis of technological innovation, product quality, and strategic partnerships. Leading firms are investing heavily in research and development to introduce next-generation diagnostic solutions that offer greater sensitivity, specificity, and ease of use. Collaborations between diagnostic companies, pharmaceutical firms, and academic institutions are common, facilitating the co-development of companion diagnostics and the translation of research findings into clinical applications. Intellectual property protection, regulatory approvals, and strong distribution networks are critical factors influencing competitive positioning in this market.

Mergers and acquisitions are playing an increasingly important role in shaping the competitive dynamics of the epigenetics diagnostic market. Established companies are acquiring innovative startups and technology providers to expand their product portfolios, access new markets, and enhance their technological capabilities. These strategic moves enable companies to stay ahead of the competition and respond to evolving customer needs. At the same time, emerging players are leveraging their agility and specialized expertise to develop disruptive technologies and carve out niche positions in the market. The influx of venture capital and private equity investment is supporting the growth of these companies and fostering a culture of innovation across the industry.

Product differentiation and customer support are key areas of focus for market participants. Companies are striving to offer comprehensive solutions that address the diverse needs of end-users, including customizable kits, high-quality reagents, advanced instruments, and integrated software platforms. Training, technical support, and after-sales services are essential components of the value proposition, particularly in the context of complex and rapidly evolving diagnostic technologies. The ability to provide end-to-end solutions and support customers throughout the diagnostic workflow is a major competitive advantage in this market.

Major companies operating in the global epigenetics diagnostic market include Illumina, Inc., Thermo Fisher Scientific, Inc., QIAGEN N.V., Merck KGaA, PerkinElmer, Inc., Abcam plc, Zymo Research Corporation, Active Motif, Inc., Diagenode (part of Hologic, Inc.), and Agilent Technologies, Inc. These companies are recognized for their extensive product portfolios, strong research and development capabilities, and global distribution networks. Illumina, for example, is a leader in sequencing technologies and offers a range of solutions for DNA methylation analysis. Thermo Fisher Scientific is known for its comprehensive offering of reagents, instruments, and software for epigenetics research and diagnostics. QIAGEN specializes in sample preparation and molecular diagnostic solutions, while Merck KGaA and PerkinElmer are prominent suppliers of reagents and analytical platforms. Emerging players such as Zymo Research and Active Motif are gaining traction with innovative kits and reagents tailored to specific epigenetic applications.

These companies are actively engaged in strategic initiatives to strengthen their market positions, including product launches, partnerships, and geographic expansion. For instance, collaborations with academic institutions and participation in large-scale research consortia enable companies to stay at the forefront of scientific advancements and accelerate the development of new diagnostic tools. The focus on regulatory compliance and quality assurance is also paramount, as companies seek to ensure the safety, efficacy, and reliability of their products in clinical settings. As the epigenetics diagnostic market continues to evolve, the ability to innovate, adapt to changing customer needs, and navigate complex regulatory environments will be critical to sustained success.

Key Players

  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • Roche Diagnostics
  • Agilent Technologies, Inc.
  • PerkinElmer, Inc.
  • Merck KGaA
  • Bio-Rad Laboratories, Inc.
  • Zymo Research Corporation
  • Active Motif, Inc.
  • Diagenode (a Hologic company)
  • Abcam plc
  • New England Biolabs, Inc.
  • Pacific Biosciences of California, Inc.
  • EpiGentek Group Inc.
  • Exact Sciences Corporation
  • Myriad Genetics, Inc.
  • Sysmex Corporation
  • Twist Bioscience Corporation
  • Oxford Nanopore Technologies plc
Epigenetics Diagnostic Market Overview

Segments

The Epigenetics Diagnostic market has been segmented on the basis of

Product Type

  • Kits
  • Reagents
  • Instruments
  • Software

Technology

  • DNA Methylation
  • Histone Modification
  • Non-coding RNA Analysis
  • Chromatin Immunoprecipitation
  • Others

Application

  • Oncology
  • Non-Oncology
  • Metabolic Diseases
  • Infectious Diseases
  • Others

End-User

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Others

Competitive Landscape

Roche Diagnostics, Thermo Fisher Scientific, Inc., Eisai Co. Ltd., and Novartis AG are key players competing in the market. To grow their market share, major players are concentrating on expanding their companies in emerging regions. Furthermore, they are implementing policies such as mergers and acquisitions, as well as the development of new technologies to enhance their market position.
 

Epigenetics Diagnostic Market By Key Players

Table Of Content

Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Epigenetics Diagnostic Market Overview
   4.1 Introduction
      4.1.1 Market Taxonomy
      4.1.2 Market Definition
      4.1.3 Macro-Economic Factors Impacting the Market Growth
   4.2 Epigenetics Diagnostic Market Dynamics
      4.2.1 Market Drivers
      4.2.2 Market Restraints
      4.2.3 Market Opportunity
   4.3 Epigenetics Diagnostic Market - Supply Chain Analysis
      4.3.1 List of Key Suppliers
      4.3.2 List of Key Distributors
      4.3.3 List of Key Consumers
   4.4 Key Forces Shaping the Epigenetics Diagnostic Market
      4.4.1 Bargaining Power of Suppliers
      4.4.2 Bargaining Power of Buyers
      4.4.3 Threat of Substitution
      4.4.4 Threat of New Entrants
      4.4.5 Competitive Rivalry
   4.5 Global Epigenetics Diagnostic Market Size & Forecast, 2023-2032
      4.5.1 Epigenetics Diagnostic Market Size and Y-o-Y Growth
      4.5.2 Epigenetics Diagnostic Market Absolute $ Opportunity

Chapter 5 Global Epigenetics Diagnostic Market Analysis and Forecast By Product Type
   5.1 Introduction
      5.1.1 Key Market Trends & Growth Opportunities By Product Type
      5.1.2 Basis Point Share (BPS) Analysis By Product Type
      5.1.3 Absolute $ Opportunity Assessment By Product Type
   5.2 Epigenetics Diagnostic Market Size Forecast By Product Type
      5.2.1 Kits
      5.2.2 Reagents
      5.2.3 Instruments
      5.2.4 Software
   5.3 Market Attractiveness Analysis By Product Type

Chapter 6 Global Epigenetics Diagnostic Market Analysis and Forecast By Technology
   6.1 Introduction
      6.1.1 Key Market Trends & Growth Opportunities By Technology
      6.1.2 Basis Point Share (BPS) Analysis By Technology
      6.1.3 Absolute $ Opportunity Assessment By Technology
   6.2 Epigenetics Diagnostic Market Size Forecast By Technology
      6.2.1 DNA Methylation
      6.2.2 Histone Modification
      6.2.3 Non-coding RNA Analysis
      6.2.4 Chromatin Immunoprecipitation
      6.2.5 Others
   6.3 Market Attractiveness Analysis By Technology

Chapter 7 Global Epigenetics Diagnostic Market Analysis and Forecast By Application
   7.1 Introduction
      7.1.1 Key Market Trends & Growth Opportunities By Application
      7.1.2 Basis Point Share (BPS) Analysis By Application
      7.1.3 Absolute $ Opportunity Assessment By Application
   7.2 Epigenetics Diagnostic Market Size Forecast By Application
      7.2.1 Oncology
      7.2.2 Non-Oncology
      7.2.3 Metabolic Diseases
      7.2.4 Infectious Diseases
      7.2.5 Others
   7.3 Market Attractiveness Analysis By Application

Chapter 8 Global Epigenetics Diagnostic Market Analysis and Forecast By End-User
   8.1 Introduction
      8.1.1 Key Market Trends & Growth Opportunities By End-User
      8.1.2 Basis Point Share (BPS) Analysis By End-User
      8.1.3 Absolute $ Opportunity Assessment By End-User
   8.2 Epigenetics Diagnostic Market Size Forecast By End-User
      8.2.1 Hospitals & Clinics
      8.2.2 Diagnostic Laboratories
      8.2.3 Academic & Research Institutes
      8.2.4 Pharmaceutical & Biotechnology Companies
      8.2.5 Others
   8.3 Market Attractiveness Analysis By End-User

Chapter 9 Global Epigenetics Diagnostic Market Analysis and Forecast by Region
   9.1 Introduction
      9.1.1 Key Market Trends & Growth Opportunities By Region
      9.1.2 Basis Point Share (BPS) Analysis By Region
      9.1.3 Absolute $ Opportunity Assessment By Region
   9.2 Epigenetics Diagnostic Market Size Forecast By Region
      9.2.1 North America
      9.2.2 Europe
      9.2.3 Asia Pacific
      9.2.4 Latin America
      9.2.5 Middle East & Africa (MEA)
   9.3 Market Attractiveness Analysis By Region

Chapter 10 Coronavirus Disease (COVID-19) Impact 
   10.1 Introduction 
   10.2 Current & Future Impact Analysis 
   10.3 Economic Impact Analysis 
   10.4 Government Policies 
   10.5 Investment Scenario

Chapter 11 North America Epigenetics Diagnostic Analysis and Forecast
   11.1 Introduction
   11.2 North America Epigenetics Diagnostic Market Size Forecast by Country
      11.2.1 U.S.
      11.2.2 Canada
   11.3 Basis Point Share (BPS) Analysis by Country
   11.4 Absolute $ Opportunity Assessment by Country
   11.5 Market Attractiveness Analysis by Country
   11.6 North America Epigenetics Diagnostic Market Size Forecast By Product Type
      11.6.1 Kits
      11.6.2 Reagents
      11.6.3 Instruments
      11.6.4 Software
   11.7 Basis Point Share (BPS) Analysis By Product Type 
   11.8 Absolute $ Opportunity Assessment By Product Type 
   11.9 Market Attractiveness Analysis By Product Type
   11.10 North America Epigenetics Diagnostic Market Size Forecast By Technology
      11.10.1 DNA Methylation
      11.10.2 Histone Modification
      11.10.3 Non-coding RNA Analysis
      11.10.4 Chromatin Immunoprecipitation
      11.10.5 Others
   11.11 Basis Point Share (BPS) Analysis By Technology 
   11.12 Absolute $ Opportunity Assessment By Technology 
   11.13 Market Attractiveness Analysis By Technology
   11.14 North America Epigenetics Diagnostic Market Size Forecast By Application
      11.14.1 Oncology
      11.14.2 Non-Oncology
      11.14.3 Metabolic Diseases
      11.14.4 Infectious Diseases
      11.14.5 Others
   11.15 Basis Point Share (BPS) Analysis By Application 
   11.16 Absolute $ Opportunity Assessment By Application 
   11.17 Market Attractiveness Analysis By Application
   11.18 North America Epigenetics Diagnostic Market Size Forecast By End-User
      11.18.1 Hospitals & Clinics
      11.18.2 Diagnostic Laboratories
      11.18.3 Academic & Research Institutes
      11.18.4 Pharmaceutical & Biotechnology Companies
      11.18.5 Others
   11.19 Basis Point Share (BPS) Analysis By End-User 
   11.20 Absolute $ Opportunity Assessment By End-User 
   11.21 Market Attractiveness Analysis By End-User

Chapter 12 Europe Epigenetics Diagnostic Analysis and Forecast
   12.1 Introduction
   12.2 Europe Epigenetics Diagnostic Market Size Forecast by Country
      12.2.1 Germany
      12.2.2 France
      12.2.3 Italy
      12.2.4 U.K.
      12.2.5 Spain
      12.2.6 Russia
      12.2.7 Rest of Europe
   12.3 Basis Point Share (BPS) Analysis by Country
   12.4 Absolute $ Opportunity Assessment by Country
   12.5 Market Attractiveness Analysis by Country
   12.6 Europe Epigenetics Diagnostic Market Size Forecast By Product Type
      12.6.1 Kits
      12.6.2 Reagents
      12.6.3 Instruments
      12.6.4 Software
   12.7 Basis Point Share (BPS) Analysis By Product Type 
   12.8 Absolute $ Opportunity Assessment By Product Type 
   12.9 Market Attractiveness Analysis By Product Type
   12.10 Europe Epigenetics Diagnostic Market Size Forecast By Technology
      12.10.1 DNA Methylation
      12.10.2 Histone Modification
      12.10.3 Non-coding RNA Analysis
      12.10.4 Chromatin Immunoprecipitation
      12.10.5 Others
   12.11 Basis Point Share (BPS) Analysis By Technology 
   12.12 Absolute $ Opportunity Assessment By Technology 
   12.13 Market Attractiveness Analysis By Technology
   12.14 Europe Epigenetics Diagnostic Market Size Forecast By Application
      12.14.1 Oncology
      12.14.2 Non-Oncology
      12.14.3 Metabolic Diseases
      12.14.4 Infectious Diseases
      12.14.5 Others
   12.15 Basis Point Share (BPS) Analysis By Application 
   12.16 Absolute $ Opportunity Assessment By Application 
   12.17 Market Attractiveness Analysis By Application
   12.18 Europe Epigenetics Diagnostic Market Size Forecast By End-User
      12.18.1 Hospitals & Clinics
      12.18.2 Diagnostic Laboratories
      12.18.3 Academic & Research Institutes
      12.18.4 Pharmaceutical & Biotechnology Companies
      12.18.5 Others
   12.19 Basis Point Share (BPS) Analysis By End-User 
   12.20 Absolute $ Opportunity Assessment By End-User 
   12.21 Market Attractiveness Analysis By End-User

Chapter 13 Asia Pacific Epigenetics Diagnostic Analysis and Forecast
   13.1 Introduction
   13.2 Asia Pacific Epigenetics Diagnostic Market Size Forecast by Country
      13.2.1 China
      13.2.2 Japan
      13.2.3 South Korea
      13.2.4 India
      13.2.5 Australia
      13.2.6 South East Asia (SEA)
      13.2.7 Rest of Asia Pacific (APAC)
   13.3 Basis Point Share (BPS) Analysis by Country
   13.4 Absolute $ Opportunity Assessment by Country
   13.5 Market Attractiveness Analysis by Country
   13.6 Asia Pacific Epigenetics Diagnostic Market Size Forecast By Product Type
      13.6.1 Kits
      13.6.2 Reagents
      13.6.3 Instruments
      13.6.4 Software
   13.7 Basis Point Share (BPS) Analysis By Product Type 
   13.8 Absolute $ Opportunity Assessment By Product Type 
   13.9 Market Attractiveness Analysis By Product Type
   13.10 Asia Pacific Epigenetics Diagnostic Market Size Forecast By Technology
      13.10.1 DNA Methylation
      13.10.2 Histone Modification
      13.10.3 Non-coding RNA Analysis
      13.10.4 Chromatin Immunoprecipitation
      13.10.5 Others
   13.11 Basis Point Share (BPS) Analysis By Technology 
   13.12 Absolute $ Opportunity Assessment By Technology 
   13.13 Market Attractiveness Analysis By Technology
   13.14 Asia Pacific Epigenetics Diagnostic Market Size Forecast By Application
      13.14.1 Oncology
      13.14.2 Non-Oncology
      13.14.3 Metabolic Diseases
      13.14.4 Infectious Diseases
      13.14.5 Others
   13.15 Basis Point Share (BPS) Analysis By Application 
   13.16 Absolute $ Opportunity Assessment By Application 
   13.17 Market Attractiveness Analysis By Application
   13.18 Asia Pacific Epigenetics Diagnostic Market Size Forecast By End-User
      13.18.1 Hospitals & Clinics
      13.18.2 Diagnostic Laboratories
      13.18.3 Academic & Research Institutes
      13.18.4 Pharmaceutical & Biotechnology Companies
      13.18.5 Others
   13.19 Basis Point Share (BPS) Analysis By End-User 
   13.20 Absolute $ Opportunity Assessment By End-User 
   13.21 Market Attractiveness Analysis By End-User

Chapter 14 Latin America Epigenetics Diagnostic Analysis and Forecast
   14.1 Introduction
   14.2 Latin America Epigenetics Diagnostic Market Size Forecast by Country
      14.2.1 Brazil
      14.2.2 Mexico
      14.2.3 Rest of Latin America (LATAM)
   14.3 Basis Point Share (BPS) Analysis by Country
   14.4 Absolute $ Opportunity Assessment by Country
   14.5 Market Attractiveness Analysis by Country
   14.6 Latin America Epigenetics Diagnostic Market Size Forecast By Product Type
      14.6.1 Kits
      14.6.2 Reagents
      14.6.3 Instruments
      14.6.4 Software
   14.7 Basis Point Share (BPS) Analysis By Product Type 
   14.8 Absolute $ Opportunity Assessment By Product Type 
   14.9 Market Attractiveness Analysis By Product Type
   14.10 Latin America Epigenetics Diagnostic Market Size Forecast By Technology
      14.10.1 DNA Methylation
      14.10.2 Histone Modification
      14.10.3 Non-coding RNA Analysis
      14.10.4 Chromatin Immunoprecipitation
      14.10.5 Others
   14.11 Basis Point Share (BPS) Analysis By Technology 
   14.12 Absolute $ Opportunity Assessment By Technology 
   14.13 Market Attractiveness Analysis By Technology
   14.14 Latin America Epigenetics Diagnostic Market Size Forecast By Application
      14.14.1 Oncology
      14.14.2 Non-Oncology
      14.14.3 Metabolic Diseases
      14.14.4 Infectious Diseases
      14.14.5 Others
   14.15 Basis Point Share (BPS) Analysis By Application 
   14.16 Absolute $ Opportunity Assessment By Application 
   14.17 Market Attractiveness Analysis By Application
   14.18 Latin America Epigenetics Diagnostic Market Size Forecast By End-User
      14.18.1 Hospitals & Clinics
      14.18.2 Diagnostic Laboratories
      14.18.3 Academic & Research Institutes
      14.18.4 Pharmaceutical & Biotechnology Companies
      14.18.5 Others
   14.19 Basis Point Share (BPS) Analysis By End-User 
   14.20 Absolute $ Opportunity Assessment By End-User 
   14.21 Market Attractiveness Analysis By End-User

Chapter 15 Middle East & Africa (MEA) Epigenetics Diagnostic Analysis and Forecast
   15.1 Introduction
   15.2 Middle East & Africa (MEA) Epigenetics Diagnostic Market Size Forecast by Country
      15.2.1 Saudi Arabia
      15.2.2 South Africa
      15.2.3 UAE
      15.2.4 Rest of Middle East & Africa (MEA)
   15.3 Basis Point Share (BPS) Analysis by Country
   15.4 Absolute $ Opportunity Assessment by Country
   15.5 Market Attractiveness Analysis by Country
   15.6 Middle East & Africa (MEA) Epigenetics Diagnostic Market Size Forecast By Product Type
      15.6.1 Kits
      15.6.2 Reagents
      15.6.3 Instruments
      15.6.4 Software
   15.7 Basis Point Share (BPS) Analysis By Product Type 
   15.8 Absolute $ Opportunity Assessment By Product Type 
   15.9 Market Attractiveness Analysis By Product Type
   15.10 Middle East & Africa (MEA) Epigenetics Diagnostic Market Size Forecast By Technology
      15.10.1 DNA Methylation
      15.10.2 Histone Modification
      15.10.3 Non-coding RNA Analysis
      15.10.4 Chromatin Immunoprecipitation
      15.10.5 Others
   15.11 Basis Point Share (BPS) Analysis By Technology 
   15.12 Absolute $ Opportunity Assessment By Technology 
   15.13 Market Attractiveness Analysis By Technology
   15.14 Middle East & Africa (MEA) Epigenetics Diagnostic Market Size Forecast By Application
      15.14.1 Oncology
      15.14.2 Non-Oncology
      15.14.3 Metabolic Diseases
      15.14.4 Infectious Diseases
      15.14.5 Others
   15.15 Basis Point Share (BPS) Analysis By Application 
   15.16 Absolute $ Opportunity Assessment By Application 
   15.17 Market Attractiveness Analysis By Application
   15.18 Middle East & Africa (MEA) Epigenetics Diagnostic Market Size Forecast By End-User
      15.18.1 Hospitals & Clinics
      15.18.2 Diagnostic Laboratories
      15.18.3 Academic & Research Institutes
      15.18.4 Pharmaceutical & Biotechnology Companies
      15.18.5 Others
   15.19 Basis Point Share (BPS) Analysis By End-User 
   15.20 Absolute $ Opportunity Assessment By End-User 
   15.21 Market Attractiveness Analysis By End-User

Chapter 16 Competition Landscape 
   16.1 Epigenetics Diagnostic Market: Competitive Dashboard
   16.2 Global Epigenetics Diagnostic Market: Market Share Analysis, 2023
   16.3 Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      16.3.1 Illumina, Inc.
Thermo Fisher Scientific Inc.
QIAGEN N.V.
Roche Diagnostics
Agilent Technologies, Inc.
PerkinElmer, Inc.
Merck KGaA
Bio-Rad Laboratories, Inc.
Zymo Research Corporation
Active Motif, Inc.
Diagenode (a Hologic company)
Abcam plc
New England Biolabs, Inc.
Pacific Biosciences of California, Inc.
EpiGentek Group Inc.
Exact Sciences Corporation
Myriad Genetics, Inc.
Sysmex Corporation
Twist Bioscience Corporation
Oxford Nanopore Technologies plc

Methodology

Our Clients

Microsoft
Dassault Aviation
Nestle SA
sinopec
Siemens Healthcare
The John Holland Group
Pfizer
Deloitte